RAD-140/YK-11

• RAD-140: 25 mg/mL
• YK-11: 25 mg/mL

RAD-140/YK-11 is evaluated as a combined formulation rather than a single active compound. Each component contributes to research-relevant biochemical pathways: As a combined formulation, mechanistic attribution generally requires comparator groups using the individual compounds, as overlapping androgen receptor signaling may obscure additive versus redundant biological effects.

• RAD-140: Studied as a selective androgen receptor modulator in models evaluating androgen receptor binding, transcriptional signaling, and downstream anabolic- and catabolic-gene expression
• YK-11: Investigated as a steroidal SARM-like compound with androgen receptor activity, commonly explored in studies involving myogenic signaling, differentiation markers, and myostatin-related pathways alongside androgen receptor-mediated effects

RAD-140/YK-11 is commonly studied in

• Androgen receptor signaling and transcriptional-activity research
• Myogenic differentiation and muscle-related gene-expression models
• Myostatin-related signaling pathways and downstream regulators of muscle growth
• Body-composition proxy models in controlled nonclinical settings where anabolic and catabolic signaling are manipulated
• Safety-pharmacology and off-target signaling studies involving androgen-pathway modulation

Reported observations are model- and protocol-dependent and may include

• Suppression-like findings in endocrine-axis measurements when systemic androgen signaling is altered
• Changes in lipid markers and liver-enzyme measurements depending on compound selection, exposure level, and study duration
• Androgen-pathway-related off-target findings that may vary according to tissue type and receptor distribution
• Confounded interpretation when combined with additional androgen-pathway modulators or substantial changes in training and dietary variables within applied research models

RAD-140/YK-11 is often explored alongside interventions that overlap with its primary mechanistic pathways.